Literature DB >> 15134859

A 25 year adventure in the field of tachykinins.

Jean-Claude Beaujouan1, Yvette Torrens, Monique Saffroy, Marie-Louise Kemel, Jacques Glowinski.   

Abstract

Several aspects of our 25 year adventure in the field of tachykinins will be successively described. They concern: substance P (SP) synthesis and release in the basal ganglia, the identification and pharmacological characterization of central tachykinin NK(1), NK(2) and NK(3) binding sites and their topographical distribution, the description of some new biological tests for corresponding receptors, the identification of tachykinin NK(1) receptor subtypes or conformers sensitive to all endogenous tachykinins (substance P, neurokinin A (NKA), neurokinin B (NKB), neuropeptide gamma (NP gamma) and neuropeptide K (NPK)) and finally, the functional involvement of these receptors and their subtypes in tachykinin-induced regulations of dopamine and acetylcholine release in the striatum.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15134859     DOI: 10.1016/j.peptides.2004.02.011

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  17 in total

Review 1.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

2.  Interactions between kisspeptin and neurokinin B in the control of GnRH secretion in the female rat.

Authors:  Víctor M Navarro; Juan M Castellano; Sarah M McConkey; Rafael Pineda; Francisco Ruiz-Pino; Leonor Pinilla; Donald K Clifton; Manuel Tena-Sempere; Robert A Steiner
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-11-02       Impact factor: 4.310

Review 3.  The significance of substance P in physiological and malignant haematopoiesis.

Authors:  Michal Nowicki; Danuta Ostalska-Nowicka; Beata Kondraciuk; Bogdan Miskowiak
Journal:  J Clin Pathol       Date:  2006-12-15       Impact factor: 3.411

4.  Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides.

Authors:  Hiral J Patel; Shakti H Ramkissoon; Prem S Patel; Pranela Rameshwar
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-16       Impact factor: 11.205

5.  Exploring the involvement of Tac2 in the mouse hippocampal stress response through gene networking.

Authors:  Mike Hook; Fuyi Xu; Elena Terenina; Wenyuan Zhao; Athena Starlard-Davenport; Pierre Mormede; Byron C Jones; Megan K Mulligan; Lu Lu
Journal:  Gene       Date:  2019-02-12       Impact factor: 3.688

6.  Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.

Authors:  A Molinos-Quintana; P Trujillo-Hacha; J I Piruat; J A Bejarano-García; E García-Guerrero; J A Pérez-Simón; Miguel Muñoz
Journal:  Invest New Drugs       Date:  2018-05-02       Impact factor: 3.850

7.  SR140333 counteracts NK-1 mediated cell proliferation in human breast cancer cell line T47D.

Authors:  Wei-Qing Huang; Ji-Gang Wang; Lei Chen; Hong-Jun Wei; Hua Chen
Journal:  J Exp Clin Cancer Res       Date:  2010-05-24

8.  The tachykinin peptide neurokinin B binds copper forming an unusual [CuII(NKB)2] complex and inhibits copper uptake into 1321N1 astrocytoma cells.

Authors:  Debora Russino; Elle McDonald; Leila Hejazi; Graeme R Hanson; Christopher E Jones
Journal:  ACS Chem Neurosci       Date:  2013-08-07       Impact factor: 4.418

9.  The neurokinin-3 (NK3) and the neurokinin-1 (NK1) receptors are differentially targeted to mesocortical and mesolimbic projection neurons and to neuronal nuclei in the rat ventral tegmental area.

Authors:  Andrée Lessard; Martin Savard; Fernand Gobeil; Joseph P Pierce; Virginia M Pickel
Journal:  Synapse       Date:  2009-06       Impact factor: 2.562

10.  The Neuropeptide Tac2 Controls a Distributed Brain State Induced by Chronic Social Isolation Stress.

Authors:  Moriel Zelikowsky; May Hui; Tomomi Karigo; Andrea Choe; Bin Yang; Mario R Blanco; Keith Beadle; Viviana Gradinaru; Benjamin E Deverman; David J Anderson
Journal:  Cell       Date:  2018-05-17       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.